查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1453897

至 2030 年精神分裂情緒障礙市場預測 - 各類型（藥物和心理治療）、原因、應用、最終用戶和地理位置的全球分析

Schizoaffective Disorders Market Forecasts to 2030 - Global Analysis By Type (Medication and Psychotherapy), Cause, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球分裂情感性疾患市場規模為 76 億美元，預計到 2030 年將達到 107 億美元，預測期內複合CAGR為 4.9%。分裂情感性疾患是一種慢性精神健康狀況，其特徵是精神分裂症症狀（例如幻覺或妄想）和情緒障礙（例如憂鬱或躁狂）的組合。患有分裂情感障礙的人通常會經歷精神病時期，在此期間他們可能難以區分真實與虛假，並伴隨嚴重的情緒障礙。治療通常包括抗精神病藥物、情緒穩定劑和心理治療的組合，以控制症狀和改善功能。

據世界衛生組織稱，2018 年，全球有 9.7 億人，即每八人中就有 1 人患有精神疾病，包括焦慮症和憂鬱症。現在，全球約有 19.86% 的成年人患有精神疾病。

市場動態：

驅動因素：

提高認知和診斷

提高市場意識和加強診斷對於及時介入和改善患者治療效果至關重要。透過有針對性的教育活動，醫療保健專業人員可以更好地識別細微的症狀，促進早期識別和適當的治療策略。此外，社區外展計劃可以使個人和家庭能夠尋求幫助，減少恥辱並為受影響的人創造一個支持性的環境。

阻礙因素：

與精神疾病相關的恥辱

儘管人們的認知有所進步，但誤解仍然存在，阻礙了接受和獲得治療。患有這種疾病的人經常面臨社會排斥和歧視，阻礙他們融入社會和就業機會。這種恥辱不僅加劇了他們的心理困擾，還阻止他們尋求幫助，從而使孤立和未經治療的症狀陷入惡性循環。因此，這是阻礙市場成長的主要因素。

機會：

專注個人化醫療

個人化醫療在這種疾病的治療領域具有巨大的前景。客製化的方法整合了遺傳、神經生物學和環境因素，為傳統的一刀切治療帶來了深刻的轉變。精準醫學使臨床醫生能夠根據患者個別特徵選擇治療方法，提高療效並最大限度地減少不良反應。因此，這些都是推動市場成長的因素。

威脅：

治療費用高

分裂情感性障礙的治療帶來了巨大的經濟負擔，費用往往達到過高的水平。這包括與藥物、治療、住院和持續精神護理相關的費用。此外，生產力和社會支持損失等間接成本進一步加劇了個人及其家庭的財務壓力。因此，治療分裂情感性疾患的高成本是阻礙市場成長的因素。

Covid-19 影響：

COVID-19 大流行對市場產生了重大影響，導致治療取得和病患照護中斷。封鎖措施、醫療機構能力下降以及將資源優先用於 COVID-19 管理導致了分裂情感障礙患者的診斷、治療啟動和治療調整的延遲。遠距醫療已成為遠距諮詢的重要工具，但數位存取和護理品質方面的差距仍然存在。

預計心理治療領域在預測期內將是最大的

預計心理治療領域在預測期內將是最大的。心理治療在分裂情感性疾患的治療中發揮著至關重要的作用，提供了與藥物治療相結合的綜合方法。認知行為治療（CBT）、支持性治療和居家治療是常用的治療方式。他們的目標是加強應對策略、改善社會功能並促進藥物依從性。

醫院部門預計在預測期內複合CAGR最高

預計醫院部門在預測期內的CAGR最高。針對分裂情感障礙市場的醫院為經歷這種複雜心理健康狀況的個人提供專門的護理。這些設施提供全面的服務，包括診斷、藥物管理、治療和支持計劃，旨在滿足分裂情感性疾患患者的獨特需求。

佔比最大的地區：

由於認知的提高、診斷技術的改進和治療方案的進步，預計北美將在預測期內佔據最大的市場佔有率。製藥公司正在投資研發，推出針對精神病和情緒症狀的新療法，改善患者的治療效果。此外，政府的支持性措施和醫療改革進一步推動市場擴張。

複合CAGR最高的地區：

預計亞太地區在預測期內的複合CAGR最高。該地區各國心理健康服務的可用性和可近性差異很大。政府有關精神衛生保健的政策和法規，包括為精神衛生服務提供資金以及支持新治療方案的研究和開發，可能會對該地區的分裂情感性障礙治療市場產生重大影響。

主要進展：

2024 年 1 月，雅培宣布美國食品藥物管理局 (FDA) 已批准其背根神經節 (DRG) 刺激療法 Proclaim(TM) DRG 神經刺激系統的擴展 MRI 標籤，該系統允許患者接受全身 MRI植入設備時進行掃描。

2023 年 9 月，雅培宣布已完成 Bigfoot Biomedical 的收購，該公司是為糖尿病患者開發智慧胰島素管理系統的領導者。

我們的報告提供了什麼：

  • 區域和國家層面的市場佔有率評估
  • 對新進入者的策略建議
  • 涵蓋2021年、2022年、2023年、2026年及2030年的市場資料
  • 市場趨勢（促進因素、限制因素、機會、威脅、課題、投資機會和建議）
  • 根據市場預測提出關鍵業務部門的策略建議
  • 競爭性景觀美化繪製主要共同趨勢
  • 公司概況，包括詳細的策略、財務狀況和最新發展
  • 反映最新技術進步的供應鏈趨勢

免費客製化產品：

本報告的所有客戶都將有權獲得以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 個）
    • 關鍵參與者的 SWOT 分析（最多 3 個）
  • 區域區隔
    • 根據客戶的興趣對任何主要國家的市場估計、預測和CAGR（註：取決於可行性檢查）
  • 競爭基準化分析
    • 根據產品組合、地理分佈和策略聯盟對主要參與者基準化分析

目錄

第 1 章：執行摘要

第 2 章：前言

  • 抽象的
  • 股東
  • 研究範圍
  • 研究方法論
    • 資料探勘
    • 數據分析
    • 數據驗證
    • 研究方法
  • 研究來源
    • 主要研究來源
    • 二手研究來源
    • 假設

第 3 章：市場趨勢分析

  • 介紹
  • 促進要素
  • 限制
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • Covid-19 的影響

第 4 章：波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭競爭

第 5 章：全球分裂情感性疾患市場：依類型

  • 介紹
  • 藥物
    • 情緒穩定劑
    • 抗精神病藥
    • 抗憂鬱藥
  • 心理治療
    • 個別治療
    • 團體治療

第 6 章：全球分裂情感性疾患市場：依原因分類

  • 介紹
  • 遺傳因素
  • 環境因素
  • 化學因素

第 7 章：全球分裂情感性疾患市場：依應用分類

  • 介紹
  • 裝置
  • 藥品
  • 診斷
  • 其他應用

第 8 章：全球分裂情感性疾患市場：依最終用戶

  • 介紹
  • 網路藥房
  • 醫院
  • 零售藥房
  • 其他最終用戶

第 9 章：全球分裂情感性疾患市場：依地理位置

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太地區其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第 10 章：主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 擴充
  • 其他關鍵策略

第 11 章：公司概況

  • Abbott Pharmaceuticals
  • AstraZeneca PLC
  • Bright Quest
  • Bristol Myers Squibb
  • Cascade Behavioural Health Hospital
  • Ciba Pharmaceuticals
  • Cleveland Clinic
  • Covington Behavioural Health Hospital
  • Delta Medical Center
  • Elan Pharmaceuticals
  • Eli Lilly and Company
  • Janssen cilag Pvt. Ltd.
  • Johnson and Johnson
  • Merz Pharma GmbH & Co.
  • Pfizer
Product Code: SMRC25449

According to Stratistics MRC, the Global Schizoaffective Disorders Market is accounted for $7.6 billion in 2023 and is expected to reach $10.7 billion by 2030 growing at a CAGR of 4.9% during the forecast period. Schizoaffective disorder is a chronic mental health condition characterized by a combination of symptoms of schizophrenia, such as hallucinations or delusions, and mood disorders, such as depression or mania. Individuals with schizoaffective disorder typically experience periods of psychosis, during which they may have difficulty distinguishing between what is real and what is not, along with significant mood disturbances. Treatment usually involves a combination of antipsychotic medications, mood stabilizers, and psychotherapy to manage symptoms and improve functioning.

According to WHO, in 2018, 970 million individuals worldwide, or 1 in every eight persons, had a mental illness, including anxiety and depressive disorders. Now, around 19.86% of adults are experiencing a mental illness worldwide.

Market Dynamics:

Driver:

Increasing awareness and diagnosis

Raising awareness and enhancing diagnosis in the market is crucial for timely intervention and improved patient outcomes. Through targeted educational campaigns, healthcare professionals can better recognize the nuanced symptoms, facilitating early identification and appropriate treatment strategies. Additionally, community outreach programs can empower individuals and families to seek help, reducing stigma and fostering a supportive environment for those affected.

Restraint:

Stigma associated with mental illness

Despite strides in awareness, misconceptions persist, hindering acceptance and access to treatment. Individuals with this disorder often face social ostracization and discrimination, impeding their integration into society and employment opportunities. This stigma not only exacerbates their psychological distress but also deters them from seeking help, perpetuating a cycle of isolation and untreated symptoms. Thus, this is the major factor impeding the growth of the market.

Opportunity:

Focus on personalized medicine

Personalized medicine holds immense promise in the treatment landscape of this disorder. Tailored approaches, integrating genetic, neurobiological, and environmental factors, offer a profound shift from traditional one-size-fits-all treatments. Precision medicine enables clinicians to select therapies based on individual patient characteristics, enhancing efficacy and minimizing adverse effects. Hence, these are the factors propelling the growth of the market.

Threat:

High cost of treatment

The treatment of schizoaffective disorder presents significant financial burdens, with costs often reaching exorbitant levels. This encompasses expenses related to medication, therapy, hospitalizations, and ongoing psychiatric care. Additionally, indirect costs such as lost productivity and social support further escalate the financial strain on individuals and their families. Therefore, the high cost of managing schizoaffective disorder is the factor hampering the growth of the market.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the market, causing disruptions in treatment access and patient care. Lockdown measures, reduced healthcare facility capacities, and prioritization of resources towards COVID-19 management led to delays in diagnosis, treatment initiation, and therapy adjustments for schizoaffective disorder patients. Telehealth emerged as a vital tool for remote consultations, but disparities in digital access and quality of care persisted.

The psychotherapy segment is expected to be the largest during the forecast period

The psychotherapy segment is expected to be the largest during the forecast period. Psychotherapy plays a crucial role in the management of Schizoaffective Disorder, offering a comprehensive approach alongside medication. Cognitive-behavioral therapy (CBT), supportive therapy, and family therapy are commonly utilized modalities. They aim to enhance coping strategies, improve social functioning, and facilitate medication adherence.

The hospitals segment is expected to have the highest CAGR during the forecast period

The hospitals segment is expected to have the highest CAGR during the forecast period. Hospitals catering to the Schizoaffective Disorders market offer specialized care tailored to individuals experiencing this complex mental health condition. These facilities provide comprehensive services, including diagnosis, medication management, therapy, and support programs, aimed at addressing the unique needs of patients with schizoaffective disorders.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by increasing awareness, improved diagnostic techniques, and advancements in treatment options. Pharmaceutical companies are investing in research and development to introduce novel therapies addressing both psychotic and affective symptoms, enhancing patient outcomes. Additionally, supportive government initiatives and healthcare reforms further propel market expansion.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. The availability and accessibility of mental health services vary widely across countries in the region. Government policies and regulations regarding mental health care, including funding for mental health services and support for research and development of new treatment options, can significantly impact the market for schizoaffective disorder treatment in the region.

Key players in the market

Some of the key players in Schizoaffective Disorders market include Abbott Pharmaceuticals, AstraZeneca PLC, Bright Quest, Bristol Myers Squibb, Cascade Behavioural Health Hospital, Ciba Pharmaceuticals, Cleveland Clinic, Covington Behavioural Health Hospital, Delta Medical Center, Elan Pharmaceuticals, Eli Lilly and Company, Janssen cilag Pvt. Ltd., Johnson and Johnson, Merz Pharma GmbH & Co. And Pfizer.

Key Developments:

In January 2024, Abbott announced that the U.S. Food and Drug Administration (FDA) has approved expanded MRI labeling for its dorsal root ganglion (DRG) stimulation therapy, the Proclaim(TM) DRG neurostimulation system, which allows patients to receive full-body MRI scans while implanted with the device.

In September 2023, Abbott announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.

Types Covered:

  • Medication
  • Psychotherapy

Causes Covered:

  • Genetic Factors
  • Environmental Factors
  • Chemical Factors

Applications Covered:

  • Devices
  • Drugs
  • Diagnostics
  • Other Applications

End Users Covered:

  • Online Pharmacy
  • Hospitals
  • Retail pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Schizoaffective Disorders Market, By Type

  • 5.1 Introduction
  • 5.2 Medication
    • 5.2.1 Mood stabilizers
    • 5.2.2 Antipsychotics
    • 5.2.3 Antidepressants
  • 5.3 Psychotherapy
    • 5.3.1 Individual Therapy
    • 5.3.2 Group Therapy

6 Global Schizoaffective Disorders Market, By Cause

  • 6.1 Introduction
  • 6.2 Genetic Factors
  • 6.3 Environmental Factors
  • 6.4 Chemical Factors

7 Global Schizoaffective Disorders Market, By Application

  • 7.1 Introduction
  • 7.2 Devices
  • 7.3 Drugs
  • 7.4 Diagnostics
  • 7.5 Other Applications

8 Global Schizoaffective Disorders Market, By End User

  • 8.1 Introduction
  • 8.2 Online Pharmacy
  • 8.3 Hospitals
  • 8.4 Retail pharmacy
  • 8.5 Other End Users

9 Global Schizoaffective Disorders Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Abbott Pharmaceuticals
  • 11.2 AstraZeneca PLC
  • 11.3 Bright Quest
  • 11.4 Bristol Myers Squibb
  • 11.5 Cascade Behavioural Health Hospital
  • 11.6 Ciba Pharmaceuticals
  • 11.7 Cleveland Clinic
  • 11.8 Covington Behavioural Health Hospital
  • 11.9 Delta Medical Center
  • 11.10 Elan Pharmaceuticals
  • 11.11 Eli Lilly and Company
  • 11.12 Janssen cilag Pvt. Ltd.
  • 11.13 Johnson and Johnson
  • 11.14 Merz Pharma GmbH & Co.
  • 11.15 Pfizer

List of Tables

  • Table 1 Global Schizoaffective Disorders Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 3 Global Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 4 Global Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 5 Global Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 6 Global Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 7 Global Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 8 Global Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 9 Global Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 10 Global Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 11 Global Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 12 Global Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 13 Global Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 14 Global Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 15 Global Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 16 Global Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 17 Global Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 18 Global Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 19 Global Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 20 Global Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 21 Global Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 22 Global Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 23 Global Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 24 North America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 25 North America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 27 North America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 28 North America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 29 North America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 30 North America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 31 North America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 32 North America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 33 North America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 34 North America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 35 North America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 36 North America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 37 North America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 38 North America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 39 North America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 40 North America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 41 North America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 42 North America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 43 North America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 44 North America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 45 North America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 46 North America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 47 Europe Stain-Resistant Fabric Market Outlook, By Country (2021-2030) ($MN)
  • Table 48 Europe Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 49 Europe Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 50 Europe Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 51 Europe Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 52 Europe Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 53 Europe Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 54 Europe Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 55 Europe Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 56 Europe Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 57 Europe Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 58 Europe Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 59 Europe Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 60 Europe Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 61 Europe Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 62 Europe Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 63 Europe Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 64 Europe Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 65 Europe Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Europe Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 67 Europe Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 68 Europe Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 69 Europe Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 70 Asia Pacific Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 71 Asia Pacific Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 72 Asia Pacific Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 73 Asia Pacific Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 74 Asia Pacific Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 75 Asia Pacific Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 76 Asia Pacific Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 77 Asia Pacific Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 78 Asia Pacific Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 79 Asia Pacific Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 80 Asia Pacific Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 81 Asia Pacific Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 82 Asia Pacific Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 83 Asia Pacific Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 84 Asia Pacific Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 85 Asia Pacific Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 86 Asia Pacific Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 87 Asia Pacific Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 88 Asia Pacific Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 89 Asia Pacific Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 90 Asia Pacific Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 91 Asia Pacific Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 92 Asia Pacific Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 93 South America Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 94 South America Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 95 South America Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 96 South America Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 97 South America Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 98 South America Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 99 South America Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 100 South America Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 101 South America Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 102 South America Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 103 South America Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 104 South America Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 105 South America Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 106 South America Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 107 South America Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 108 South America Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 109 South America Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 110 South America Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 111 South America Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 112 South America Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 113 South America Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 114 South America Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 115 South America Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 116 Middle East & Africa Schizoaffective Disorders Market Outlook, By Country (2021-2030) ($MN)
  • Table 117 Middle East & Africa Schizoaffective Disorders Market Outlook, By Type (2021-2030) ($MN)
  • Table 118 Middle East & Africa Schizoaffective Disorders Market Outlook, By Medication (2021-2030) ($MN)
  • Table 119 Middle East & Africa Schizoaffective Disorders Market Outlook, By Mood stabilizers (2021-2030) ($MN)
  • Table 120 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antipsychotics (2021-2030) ($MN)
  • Table 121 Middle East & Africa Schizoaffective Disorders Market Outlook, By Antidepressants (2021-2030) ($MN)
  • Table 122 Middle East & Africa Schizoaffective Disorders Market Outlook, By Psychotherapy (2021-2030) ($MN)
  • Table 123 Middle East & Africa Schizoaffective Disorders Market Outlook, By Individual Therapy (2021-2030) ($MN)
  • Table 124 Middle East & Africa Schizoaffective Disorders Market Outlook, By Group Therapy (2021-2030) ($MN)
  • Table 125 Middle East & Africa Schizoaffective Disorders Market Outlook, By Cause (2021-2030) ($MN)
  • Table 126 Middle East & Africa Schizoaffective Disorders Market Outlook, By Genetic Factors (2021-2030) ($MN)
  • Table 127 Middle East & Africa Schizoaffective Disorders Market Outlook, By Environmental Factors (2021-2030) ($MN)
  • Table 128 Middle East & Africa Schizoaffective Disorders Market Outlook, By Chemical Factors (2021-2030) ($MN)
  • Table 129 Middle East & Africa Schizoaffective Disorders Market Outlook, By Application (2021-2030) ($MN)
  • Table 130 Middle East & Africa Schizoaffective Disorders Market Outlook, By Devices (2021-2030) ($MN)
  • Table 131 Middle East & Africa Schizoaffective Disorders Market Outlook, By Drugs (2021-2030) ($MN)
  • Table 132 Middle East & Africa Schizoaffective Disorders Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 133 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 134 Middle East & Africa Schizoaffective Disorders Market Outlook, By End User (2021-2030) ($MN)
  • Table 135 Middle East & Africa Schizoaffective Disorders Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 136 Middle East & Africa Schizoaffective Disorders Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 137 Middle East & Africa Schizoaffective Disorders Market Outlook, By Retail pharmacy (2021-2030) ($MN)
  • Table 138 Middle East & Africa Schizoaffective Disorders Market Outlook, By Other End Users (2021-2030) ($MN)